Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple breathing machine replace Blood-Letting for High-Altitude disease?

NCT ID NCT07600086

Disease control Sponsor: Tibet Autonomous Region People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a non-invasive ventilator (a mask that helps you breathe at night) can lower hemoglobin levels in people with high-altitude polycythemia, a condition where the blood becomes too thick due to low oxygen. About 70 adults living at high altitudes will either receive standard care or standard care plus nightly ventilator use. The main goal is to see if hemoglobin drops after 3 and 6 months, which would mean less strain on the heart and blood vessels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
non-invasive ventilator (CPAP or BiPAP)
What this could lead to
If it works, this could offer a new, drug-free way to manage high-altitude polycythemia and reduce the risk of complications like blood clots.
What could go wrong
This is a small, early-stage study with only 70 participants, so results may not apply to everyone. The treatment requires wearing a mask during sleep, which some may find uncomfortable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed with high-altitude polycythemia (HAPC). 2. Aged 18 years or older, with no gender restriction. 3. Voluntarily participate in the study and sign the informed consent form. Exclusion Criteria: 1. Disturbance of consciousness. 2. Inability to independently clear airway secretions, with the risk of aspiration. 3. Severe upper gastrointestinal bleeding. 4. Hemodynamic instability. 5. Upper airway obstruction. 6. Un drained pneumothorax or mediastinal emphysema. 7. Conditions that prevent mask wearing, such as facial trauma or deformity. 8. Patient non-compliance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HAPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic mountain sickness

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAPC High-altitude polycythemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • People's Hospital of Xizang Autonomous Region；Lhasa, Xizang Autonomous Region, China, 850000

    Xizang, China

  • Xizang Autonomous Region People's Hospital

    Xizang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.